FDA Issues 43 Product-Specific Guidances

Comprises 33 New Guidances And 10 Revised Documents

The latest update from the FDA has brought 43 new and updated product-specific guidances for generic drug development, including dedicated documents on complex generics such as aerosols, powders and sprays.

43
The FDA has issued 43 new and revised product-specific guidances • Source: Shutterstock

The latest update from the US Food and Drug Administration in early March has brought 43 draft new and updated product-specific guidances for generic drug development, comprising 33 new guidances and 10 revised documents.

Among the latest documents are new draft guidances dedicated to besifloxacin hydrochloride suspension and clevidipine emulsion, as well as...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.